PE20220515A1 - Nuevos compuestos heterociclicos - Google Patents
Nuevos compuestos heterociclicosInfo
- Publication number
- PE20220515A1 PE20220515A1 PE2021002265A PE2021002265A PE20220515A1 PE 20220515 A1 PE20220515 A1 PE 20220515A1 PE 2021002265 A PE2021002265 A PE 2021002265A PE 2021002265 A PE2021002265 A PE 2021002265A PE 20220515 A1 PE20220515 A1 PE 20220515A1
- Authority
- PE
- Peru
- Prior art keywords
- oxazin
- methanone
- chloro
- phenyl
- disease
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 abstract 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- MEVWFIYKADFWTN-SBUREZEXSA-N C1CN2C[C@](OC[C@@H]2CN1C(=O)C3=CC=CC(=C3)C4=C(NN=C4)F)(C5=CC(=C(C=C5)F)F)O Chemical compound C1CN2C[C@](OC[C@@H]2CN1C(=O)C3=CC=CC(=C3)C4=C(NN=C4)F)(C5=CC(=C(C=C5)F)F)O MEVWFIYKADFWTN-SBUREZEXSA-N 0.000 abstract 1
- COUMWMYHBSXJJI-IFXJQAMLSA-N CC1=CC(=NC=C1Cl)[C@H]2CN3CCN(C[C@H]3CO2)C(=O)C4=C(C(=CC=C4)OC)Cl Chemical compound CC1=CC(=NC=C1Cl)[C@H]2CN3CCN(C[C@H]3CO2)C(=O)C4=C(C(=CC=C4)OC)Cl COUMWMYHBSXJJI-IFXJQAMLSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185088 | 2019-07-09 | ||
| PCT/EP2020/069074 WO2021005034A1 (en) | 2019-07-09 | 2020-07-07 | New heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220515A1 true PE20220515A1 (es) | 2022-04-07 |
Family
ID=67220669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002265A PE20220515A1 (es) | 2019-07-09 | 2020-07-07 | Nuevos compuestos heterociclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220242876A1 (https=) |
| EP (1) | EP3997096B1 (https=) |
| JP (1) | JP7649283B2 (https=) |
| KR (1) | KR20220034104A (https=) |
| CN (1) | CN114096545A (https=) |
| AR (1) | AR119376A1 (https=) |
| AU (1) | AU2020311584A1 (https=) |
| BR (1) | BR112021026899A2 (https=) |
| CA (1) | CA3145338A1 (https=) |
| CL (1) | CL2022000019A1 (https=) |
| CO (1) | CO2022000186A2 (https=) |
| CR (1) | CR20220004A (https=) |
| IL (1) | IL288987A (https=) |
| MX (1) | MX2022000243A (https=) |
| PE (1) | PE20220515A1 (https=) |
| PH (1) | PH12021553249A1 (https=) |
| TW (1) | TW202116781A (https=) |
| WO (1) | WO2021005034A1 (https=) |
| ZA (1) | ZA202110352B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| CN114269755A (zh) | 2019-09-12 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014001946A (es) * | 2011-08-19 | 2014-03-27 | Merck Sharp & Dohme | Inhibidores del canal de potasio medularmente externo renal. |
| US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| JP7257387B2 (ja) * | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| WO2019134985A1 (en) * | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| MX2022000083A (es) * | 2019-07-03 | 2022-02-03 | Hoffmann La Roche | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos. |
-
2020
- 2020-07-07 CN CN202080050165.3A patent/CN114096545A/zh active Pending
- 2020-07-07 AU AU2020311584A patent/AU2020311584A1/en not_active Abandoned
- 2020-07-07 CR CR20220004A patent/CR20220004A/es unknown
- 2020-07-07 PH PH1/2021/553249A patent/PH12021553249A1/en unknown
- 2020-07-07 JP JP2022500908A patent/JP7649283B2/ja active Active
- 2020-07-07 CA CA3145338A patent/CA3145338A1/en active Pending
- 2020-07-07 BR BR112021026899A patent/BR112021026899A2/pt not_active Application Discontinuation
- 2020-07-07 MX MX2022000243A patent/MX2022000243A/es unknown
- 2020-07-07 EP EP20740259.5A patent/EP3997096B1/en active Active
- 2020-07-07 WO PCT/EP2020/069074 patent/WO2021005034A1/en not_active Ceased
- 2020-07-07 KR KR1020227000611A patent/KR20220034104A/ko not_active Ceased
- 2020-07-07 PE PE2021002265A patent/PE20220515A1/es unknown
- 2020-07-08 TW TW109123050A patent/TW202116781A/zh unknown
- 2020-07-08 AR ARP200101928A patent/AR119376A1/es not_active Application Discontinuation
-
2021
- 2021-12-13 ZA ZA2021/10352A patent/ZA202110352B/en unknown
- 2021-12-14 IL IL288987A patent/IL288987A/en unknown
-
2022
- 2022-01-04 CL CL2022000019A patent/CL2022000019A1/es unknown
- 2022-01-06 US US17/569,749 patent/US20220242876A1/en active Pending
- 2022-01-13 CO CONC2022/0000186A patent/CO2022000186A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553249A1 (en) | 2023-02-27 |
| BR112021026899A2 (pt) | 2022-05-10 |
| EP3997096A1 (en) | 2022-05-18 |
| ZA202110352B (en) | 2022-08-31 |
| TW202116781A (zh) | 2021-05-01 |
| CR20220004A (es) | 2022-01-31 |
| WO2021005034A1 (en) | 2021-01-14 |
| EP3997096C0 (en) | 2024-08-28 |
| CL2022000019A1 (es) | 2022-10-21 |
| IL288987A (en) | 2022-02-01 |
| CO2022000186A2 (es) | 2022-01-17 |
| AR119376A1 (es) | 2021-12-15 |
| JP7649283B2 (ja) | 2025-03-19 |
| EP3997096B1 (en) | 2024-08-28 |
| KR20220034104A (ko) | 2022-03-17 |
| MX2022000243A (es) | 2022-02-03 |
| JP2022539604A (ja) | 2022-09-12 |
| US20220242876A1 (en) | 2022-08-04 |
| AU2020311584A1 (en) | 2022-01-20 |
| CA3145338A1 (en) | 2021-01-14 |
| CN114096545A (zh) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220515A1 (es) | Nuevos compuestos heterociclicos | |
| PE20220514A1 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos | |
| PE20211380A1 (es) | Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa | |
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| JO3032B1 (ar) | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. | |
| PH12021550381A1 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| PH12015502323A1 (en) | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents | |
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
| MX2010009658A (es) | Derivados de azetidina. | |
| JP2019535825A5 (https=) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| JOP20200304A1 (ar) | مركبات بنزينسلفوناميد واستخدامها كعوامل علاجية | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| SA520420382B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 | |
| JP2025516005A5 (https=) | ||
| TN2020000161A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| PL1648904T3 (pl) | Związki N-sulfonyloheterocyklopirolioalkiloaminowe jako ligandy 5-hydroksytryptaminy-6 | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 |